2026 Q1 -tulosraportti
75 päivää sitten
‧29 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenNow the previously mentioned TED tender is over. As I have said, it is very complicated, so with good help from AI, I have arrived at the following It is Bioporto's NGAL test that the hospital in Romania has chosen. The value is 87.5 Danish kroner. the duration is over 4 years. (EU requirement that one may not enter into long-term agreements) For the sake of good order, the money will be transferred continuously. The entire agreement is stated below. The hospital has entered into a total framework agreement with a maximum framework value of 58,076,651.22 RON (corresponding to approximately 87.5 million Danish kroner).It is important to distinguish between the framework agreement's framework amount and the actual, implemented contracts: The framework agreement's maximum ceiling: The hospital can purchase for up to 58.07 million RON over the next 48 months. Implemented so far: The specific value of the contracts actually awarded and signed in this specific announcement amounts to 12,746,774.59 RON (approximately 19.2 million Danish kroner).The agreement is divided into sub-agreements (lots), where LOT-0001 (reagents for Abbott Alinity biochemistry and immunology) constitutes the absolute largest part with a maximum budgeted ceiling of 50,057,313.90 RON .(50,057,313.90 RON corresponds to approximately 75.6 million Danish kroner.) https://ted.europa.eu/en/search/result?publication-number=523285-2026&search-scope=ALL&scope=ALL&onlyLatestVersions=false&sortColumn=publication-number&sortOrder=DESC&page=1&simpleSearchRef=true
800 pcs at 80 kr (highly estimated) = 64.000/year That is probably not the deal that will really move the stock price.- ·3 päivää sittenI just discovered this from LinkedIn. I think this is relevant news because the treatment centers are in the process of complying with the various recommendations that KDIGO published in the spring. KDIGO's guideline update on biomarker use, and what the implementation actually looks like in a clinical laboratory. https://www.linkedin.com/feed/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7487529288464760835&highlightedUpdateType=NETWORK_CONVERSATIONS&origin=EMAIL
- ·29.7.Update from TED. Tenders for NGAL-tests have now started to emerge (there have been no tenders here over the summer). The current tender is designed based on KDIGO's new recommendations as well as the machines validated for the test. However, it will be a few months before we find out if it is BioPorto's test that wins the order, as the formal EU tender rules and deadlines must be complied with.My best recommendation to everyone who is in this stock and has been since PME as CEO, is to stay until 2026 and make a decision based on what is happening currently, with this management that is in place today. This management that is in place today has as its first priority to have as much sales as possible, so they do not have to ask for more money from the shareholders and money to develop the test and other things. Regarding sales, KDIGO's strong recommendations for the NGAL test are the reason why Bioporto is on the verge of a global breakthrough. We do not know when the final documents will be ready, but expect them to be ready by this autumn at the latest Here in the EU, we can follow along with TED as hospitals and other treatment centers will introduce the NGAL test. In the USA, we can only follow along when they close agreements with the various hospitals that are to participate in the research. Right now, they have closed agreements with 12 hospitals and what we are waiting for is for them to open up for the last 8 hospitals that are to participate in the research for the NGAL test for adults. Once these 8 hospitals are found and the agreement is closed, it will be impossible for us to follow whether more hospitals are added in the USA, because they simply order directly from Bioporto's partner. I thought I might as well take the opportunity to provide a summary, so we are all updated. I think I included everything.
·23.7. · MuokattuImpressive. The closing auction opens with a match at a price of 1.185 for a total of 47 shares. Interesting if it holds until 16.59. Yesterday there was no match and the turnover currently indicates almost 50 kr today. What "progress". Lesson: Investing in illiquid shares is associated with a high risk that one trades the share at an unfair price.
Once again, hot air from your side - life is too short to waste on your complaints.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
75 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenNow the previously mentioned TED tender is over. As I have said, it is very complicated, so with good help from AI, I have arrived at the following It is Bioporto's NGAL test that the hospital in Romania has chosen. The value is 87.5 Danish kroner. the duration is over 4 years. (EU requirement that one may not enter into long-term agreements) For the sake of good order, the money will be transferred continuously. The entire agreement is stated below. The hospital has entered into a total framework agreement with a maximum framework value of 58,076,651.22 RON (corresponding to approximately 87.5 million Danish kroner).It is important to distinguish between the framework agreement's framework amount and the actual, implemented contracts: The framework agreement's maximum ceiling: The hospital can purchase for up to 58.07 million RON over the next 48 months. Implemented so far: The specific value of the contracts actually awarded and signed in this specific announcement amounts to 12,746,774.59 RON (approximately 19.2 million Danish kroner).The agreement is divided into sub-agreements (lots), where LOT-0001 (reagents for Abbott Alinity biochemistry and immunology) constitutes the absolute largest part with a maximum budgeted ceiling of 50,057,313.90 RON .(50,057,313.90 RON corresponds to approximately 75.6 million Danish kroner.) https://ted.europa.eu/en/search/result?publication-number=523285-2026&search-scope=ALL&scope=ALL&onlyLatestVersions=false&sortColumn=publication-number&sortOrder=DESC&page=1&simpleSearchRef=true800 pcs at 80 kr (highly estimated) = 64.000/year That is probably not the deal that will really move the stock price.
- ·3 päivää sittenI just discovered this from LinkedIn. I think this is relevant news because the treatment centers are in the process of complying with the various recommendations that KDIGO published in the spring. KDIGO's guideline update on biomarker use, and what the implementation actually looks like in a clinical laboratory. https://www.linkedin.com/feed/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7487529288464760835&highlightedUpdateType=NETWORK_CONVERSATIONS&origin=EMAIL
- ·29.7.Update from TED. Tenders for NGAL-tests have now started to emerge (there have been no tenders here over the summer). The current tender is designed based on KDIGO's new recommendations as well as the machines validated for the test. However, it will be a few months before we find out if it is BioPorto's test that wins the order, as the formal EU tender rules and deadlines must be complied with.My best recommendation to everyone who is in this stock and has been since PME as CEO, is to stay until 2026 and make a decision based on what is happening currently, with this management that is in place today. This management that is in place today has as its first priority to have as much sales as possible, so they do not have to ask for more money from the shareholders and money to develop the test and other things. Regarding sales, KDIGO's strong recommendations for the NGAL test are the reason why Bioporto is on the verge of a global breakthrough. We do not know when the final documents will be ready, but expect them to be ready by this autumn at the latest Here in the EU, we can follow along with TED as hospitals and other treatment centers will introduce the NGAL test. In the USA, we can only follow along when they close agreements with the various hospitals that are to participate in the research. Right now, they have closed agreements with 12 hospitals and what we are waiting for is for them to open up for the last 8 hospitals that are to participate in the research for the NGAL test for adults. Once these 8 hospitals are found and the agreement is closed, it will be impossible for us to follow whether more hospitals are added in the USA, because they simply order directly from Bioporto's partner. I thought I might as well take the opportunity to provide a summary, so we are all updated. I think I included everything.
- ·23.7. · MuokattuImpressive. The closing auction opens with a match at a price of 1.185 for a total of 47 shares. Interesting if it holds until 16.59. Yesterday there was no match and the turnover currently indicates almost 50 kr today. What "progress". Lesson: Investing in illiquid shares is associated with a high risk that one trades the share at an unfair price.Once again, hot air from your side - life is too short to waste on your complaints.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
75 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenNow the previously mentioned TED tender is over. As I have said, it is very complicated, so with good help from AI, I have arrived at the following It is Bioporto's NGAL test that the hospital in Romania has chosen. The value is 87.5 Danish kroner. the duration is over 4 years. (EU requirement that one may not enter into long-term agreements) For the sake of good order, the money will be transferred continuously. The entire agreement is stated below. The hospital has entered into a total framework agreement with a maximum framework value of 58,076,651.22 RON (corresponding to approximately 87.5 million Danish kroner).It is important to distinguish between the framework agreement's framework amount and the actual, implemented contracts: The framework agreement's maximum ceiling: The hospital can purchase for up to 58.07 million RON over the next 48 months. Implemented so far: The specific value of the contracts actually awarded and signed in this specific announcement amounts to 12,746,774.59 RON (approximately 19.2 million Danish kroner).The agreement is divided into sub-agreements (lots), where LOT-0001 (reagents for Abbott Alinity biochemistry and immunology) constitutes the absolute largest part with a maximum budgeted ceiling of 50,057,313.90 RON .(50,057,313.90 RON corresponds to approximately 75.6 million Danish kroner.) https://ted.europa.eu/en/search/result?publication-number=523285-2026&search-scope=ALL&scope=ALL&onlyLatestVersions=false&sortColumn=publication-number&sortOrder=DESC&page=1&simpleSearchRef=true800 pcs at 80 kr (highly estimated) = 64.000/year That is probably not the deal that will really move the stock price.
- ·3 päivää sittenI just discovered this from LinkedIn. I think this is relevant news because the treatment centers are in the process of complying with the various recommendations that KDIGO published in the spring. KDIGO's guideline update on biomarker use, and what the implementation actually looks like in a clinical laboratory. https://www.linkedin.com/feed/?highlightedUpdateUrn=urn%3Ali%3Aactivity%3A7487529288464760835&highlightedUpdateType=NETWORK_CONVERSATIONS&origin=EMAIL
- ·29.7.Update from TED. Tenders for NGAL-tests have now started to emerge (there have been no tenders here over the summer). The current tender is designed based on KDIGO's new recommendations as well as the machines validated for the test. However, it will be a few months before we find out if it is BioPorto's test that wins the order, as the formal EU tender rules and deadlines must be complied with.My best recommendation to everyone who is in this stock and has been since PME as CEO, is to stay until 2026 and make a decision based on what is happening currently, with this management that is in place today. This management that is in place today has as its first priority to have as much sales as possible, so they do not have to ask for more money from the shareholders and money to develop the test and other things. Regarding sales, KDIGO's strong recommendations for the NGAL test are the reason why Bioporto is on the verge of a global breakthrough. We do not know when the final documents will be ready, but expect them to be ready by this autumn at the latest Here in the EU, we can follow along with TED as hospitals and other treatment centers will introduce the NGAL test. In the USA, we can only follow along when they close agreements with the various hospitals that are to participate in the research. Right now, they have closed agreements with 12 hospitals and what we are waiting for is for them to open up for the last 8 hospitals that are to participate in the research for the NGAL test for adults. Once these 8 hospitals are found and the agreement is closed, it will be impossible for us to follow whether more hospitals are added in the USA, because they simply order directly from Bioporto's partner. I thought I might as well take the opportunity to provide a summary, so we are all updated. I think I included everything.
- ·23.7. · MuokattuImpressive. The closing auction opens with a match at a price of 1.185 for a total of 47 shares. Interesting if it holds until 16.59. Yesterday there was no match and the turnover currently indicates almost 50 kr today. What "progress". Lesson: Investing in illiquid shares is associated with a high risk that one trades the share at an unfair price.Once again, hot air from your side - life is too short to waste on your complaints.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt